Mirum Pharmaceuticals MIRM 深 滬
已收盤 05-15 16:00:00 美东时间
102.185
-9.205
-8.26%
華盛通- 最 高110.25
- 今 開109.47
- 成交量 167.27万股
- 最 低 101.96
- 昨 收 111.39
- 總市值 62.31亿
- 52周最高 114.99
- 市盈率 靜 --
- 換手率 2.74%
- 52周最低 43.30
- 委 比 83.49%
- 總股本 6097.78万
- 歷史最高 114.99
- 量 比 0.79
- 振 幅 7.44%
- 歷史最低 6.513
- 每 手 1
- 風險率 18.51%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology
U.S. RESEARCH ROUNDUP- Cisco, DTE Energy, Marvell Technology May 14 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cisco, DTE Energy and Marvell Technology on Thursday. HIGHLIGHTS * Cheesecake Factory Inc CAKE.O : JP M
05-14 15:24
Mirum Pharmaceuticals prices $600M senior notes
Mirum Pharmaceuticals (MIRM) priced a private offering of $600M aggregate principal amount of 0.00% convertible senior notes due 2032. The initial purchasers have a 13-day option to buy up to an addit...
05-13 13:58
Mirum Pharmaceuticals Announces Proposed $600M Offering Of Notes Due 2032
Miram Pharmaceuticals to offer, subject to market conditions and other factors, $600.0 million aggregate principal amount of convertible senior notes due 2032 (the "notes") in a private placement (the "offering") to
05-13 04:19
Mirum Pharmaceuticals (MIRM) Gets a Buy from H.C. Wainwright
In a report released today, Swayampakula Ramakanth from H.C. Wainwright assigne...
05-12 18:43
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
Baird Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $129
Baird analyst Brian Skorney maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $112 to $129.
05-07 19:44
Mirum Pharmaceuticals Signals Growth Amid Heavy Investment
Mirum Pharmaceuticals (($MIRM)) has held its Q1 earnings call. Read on for the ...
05-07 09:12
财报速睇 | Mirum Pharmaceuticals 2026财年Q1营收1.60亿美元，同比增长43.3%；归母净利润亏损7.90亿美元，同比亏损扩大5283.7%
华盛资讯5月7日讯，Mirum Pharmaceuticals公布2026财年Q1业绩，公司Q1营收1.60亿美元，同比增长43.3%，归母净利润亏损7.90亿美元，同比亏损扩大5283.7%。
05-07 05:04
Earnings Scheduled For May 6, 2026
Companies Reporting Before The Bell • Deluxe (NYSE:DLX) is expected to report q...
05-07 05:03
Mirum Pharmaceuticals Raises FY2026 Sales Guidance from $630.000M-$650.000M to $660.000M-$680.000M vs $644.905M Est
Mirum Pharmaceuticals (NASDAQ:MIRM) raises FY2026 sales outlook from $630.000 million-$650.000 million to $660.000 million-$680.000 million vs $644.905 million estimate.
05-07 04:04
